Status:
UNKNOWN
Impact of Mirabegron on Erectile Function in BPH Patients
Lead Sponsor:
Kasr El Aini Hospital
Conditions:
Males With Benign Prostatic Hyperplasia Symptoms
Eligibility:
MALE
50+ years
Brief Summary
Evaluation of impact of Mirabegron on erectile function for patients treated for BPH
Detailed Description
50 patients (Group A) will receive Mirabegron \& alpha blocker 50 patients (Group B) will receive alpha blocker only Evaluation using IIEF 5 scoring system
Eligibility Criteria
Inclusion
- All males above age 50 with LUTS due to BPH not candidate for prostatectomy
Exclusion
- males below age 50
- neurologic abnormality
- Any indication for prostatectomy
- abnormal bladder contractility i.e diabetics
Key Trial Info
Start Date :
October 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04503850
Start Date
October 1 2020
End Date
October 1 2021
Last Update
August 10 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.